FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer
FDA approval · BioPharm International · 2026-10-15. Number 1 in the UrologyWatch Top 5 for October 16, 2026.
FDA broadened the approval of nogapendekin alfa inbakicept (Anktiva, N-803) to include patients with papillary-only BCG-unresponsive non-muscle invasive bladder cancer, expanding its prior approval for CIS.
Why it matters: Gives clinicians an added intravesical option for BCG-unresponsive papillary disease, an area with limited bladder-sparing alternatives.
Source: BioPharm International
Loading today's edition…